In addition to warfarin, the family of vitamin K antagonist (VKA) oral anticoagulants includes
acenocoumarol, phenprocoumon, phenindione and fluindione. 1 These drugs alter the …

Background and Purpose—Several randomized trials and real-world studies have reported
the efficacy and safety of non–vitamin K antagonist oral anticoagulants (NOACs) in Asian …

Nonvitamin K antagonist oral anticoagulants (NOACs) have been proposed as an
alternative to vitamin K antagonists in atrial fibrillation (AF) patients but the comparative …

Aims Non-vitamin K antagonist oral anticoagulants (NOACs) require dose reductions
according to patient or clinical factors for patients with atrial fibrillation (AF). In this meta …

Non-vitamin K antagonist oral anticoagulants (NOACs) were developed and approved as
substitutes for vitamin K antagonists (VKAs)[1–3]. NOACs have become the preferred …

Background We evaluated the dose-dependent efficacy, safety, and all-cause mortality of
non-vitamin K antagonist oral anticoagulants (NOACs) in “atrial fibrillation (AF) patients who …

Atrial fibrillation (AF) confers increased risk of stroke and other thromboembolic events, and
oral anticoagulation therefore is the essential part of AF management to reduce the risk of …

Anticoagulation is fundamental in the management of patients with atrial fibrillation (AF). The
study aims to provide a comparative review of the major phase III randomized clinical trials …

Background: Recent observational studies have compared effectiveness and safety profiles
between non-vitamin K antagonist oral anticoagulants (NOACs) and warfarin in patients with …

Aim Four non‐vitamin K oral anticoagulants (NOAC s) have been evaluated in clinical trials
for the prevention of stroke in patients with atrial fibrillation (AF). Although each of the NOAC …